PriceTargets.com logo

Xeris Biopharma - XERS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $6.25
  • Forecasted Upside: 24.25%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$5.03 As of 05/9/2025 04:58 PM ET
▼ -0.13 (-2.52%)

This chart shows the closing price for XERS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarAprMay$5.03Closing price on 05/10/25:
Get New Xeris Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XERS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XERS

Analyst Price Target is $6.25
▲ +24.25% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Xeris Biopharma in the last 3 months. The average price target is $6.25, with a high forecast of $8.00 and a low forecast of $4.00. The average price target represents a 24.25% upside from the last price of $5.03.

This chart shows the closing price for XERS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
5/248/2411/242/255/255/26$1.23$2.92$4.62$6.31$8Closing price on 05/10/25: $5.03High$8.00Average$6.25Low$4.00




Current Consensus is Moderate Buy

The current consensus among 6 contributing investment analysts is to moderate buy stock in Xeris Biopharma. This rating has held steady since November 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/16/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/16/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/14/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/12/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/10/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/11/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/11/2025

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/9/2025OppenheimerBoost TargetOutperform ➝ Outperform$6.00 ➝ $7.00
3/7/2025Leerink PartnersBoost TargetOutperform ➝ Outperform$5.00 ➝ $6.00
3/7/2025Craig HallumBoost TargetBuy ➝ Buy$5.00 ➝ $6.50
3/7/2025Piper SandlerReiterated RatingNeutral ➝ Neutral$3.00 ➝ $4.00
3/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$6.60 ➝ $8.00
1/29/2025Jefferies Financial GroupReiterated RatingBuy ➝ Buy$4.00 ➝ $6.00
11/11/2024HC WainwrightBoost TargetBuy ➝ Buy$6.00 ➝ $6.60
11/11/2024Piper SandlerDowngradeOverweight ➝ Neutral$3.00 ➝ $3.00
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
5/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
5/10/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$4.00 ➝ $3.00
3/28/2024OppenheimerInitiated CoverageOutperform$5.00
3/7/2024HC WainwrightBoost TargetBuy ➝ Buy$5.50 ➝ $6.00
11/13/2023HC WainwrightLower TargetBuy ➝ Buy$6.00 ➝ $5.50
11/10/2023Piper SandlerLower TargetOverweight ➝ Overweight$5.00 ➝ $4.00
8/28/2023Craig HallumInitiated CoverageBuy$4.50
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00
3/9/2023HC WainwrightReiterated RatingBuy$6.00
1/27/2023Leerink PartnersLower TargetOutperform$6.00 ➝ $5.00
10/20/2022Jefferies Financial GroupInitiated CoverageBuy$4.00
4/28/2022Craig HallumInitiated CoverageBuy$6.50
3/16/2022MizuhoLower TargetBuy$8.00 ➝ $6.00
3/11/2022HC WainwrightReiterated RatingBuy$8.00 ➝ $6.00
2/16/2022Leerink PartnersLower TargetOutperform$8.00 ➝ $6.00
12/31/2021Leerink PartnersBoost TargetOutperform$6.00 ➝ $8.00
12/31/2021HC WainwrightBoost TargetBuy$4.25 ➝ $5.40
12/16/2021Leerink PartnersReiterated RatingBuy$6.00
11/17/2021Leerink PartnersInitiated CoverageOutperform$6.00
11/11/2021HC WainwrightBoost TargetBuy$4.00 ➝ $4.25
10/29/2021HC WainwrightInitiated CoverageBuy$4.00
5/25/2021MizuhoLower TargetBuy$14.00 ➝ $9.00
11/27/2020MizuhoReiterated RatingBuy$14.00
8/11/2020MizuhoReiterated RatingBuy$14.00
6/30/2020Royal Bank of CanadaReiterated RatingOutperform ➝ Market Perform$15.00
6/30/2020Leerink PartnersReiterated RatingBuy ➝ Market Perform$10.00
5/26/2020MizuhoReiterated RatingBuy$14.00
(Data available from 5/11/2020 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/12/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/11/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/11/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/10/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/9/2025
  • 7 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/11/2025
  • 10 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/10/2025
  • 12 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/10/2025

Current Sentiment

  • 12 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Xeris Biopharma logo
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $5.03
Low: $5.00
High: $5.23

50 Day Range

MA: $4.66
Low: $3.77
High: $5.87

52 Week Range

Now: $5.03
Low: $1.77
High: $6.07

Volume

2,547,354 shs

Average Volume

1,935,486 shs

Market Capitalization

$786.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Xeris Biopharma?

The following Wall Street sell-side analysts have issued research reports on Xeris Biopharma in the last year: Craig Hallum, HC Wainwright, Jefferies Financial Group Inc., Leerink Partners, Oppenheimer Holdings Inc., and Piper Sandler.
View the latest analyst ratings for XERS.

What is the current price target for Xeris Biopharma?

0 Wall Street analysts have set twelve-month price targets for Xeris Biopharma in the last year. Their average twelve-month price target is $6.25, suggesting a possible upside of 24.3%. HC Wainwright has the highest price target set, predicting XERS will reach $8.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $4.00 for Xeris Biopharma in the next year.
View the latest price targets for XERS.

What is the current consensus analyst rating for Xeris Biopharma?

Xeris Biopharma currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for XERS.

What other companies compete with Xeris Biopharma?

Other companies that are similar to Xeris Biopharma include Xenon Pharmaceuticals, MorphoSys, Protagonist Therapeutics, MoonLake Immunotherapeutics and HUTCHMED. Learn More about companies similar to Xeris Biopharma.

How do I contact Xeris Biopharma's investor relations team?

Xeris Biopharma's physical mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company's listed phone number is (844) 445-5704 and its investor relations email address is ir@xerispharma.com. The official website for Xeris Biopharma is www.xerispharma.com. Learn More about contacing Xeris Biopharma investor relations.





Receive Xeris Biopharma News & Ratings Daily
Sign up to receive the latest news and ratings for Xeris Biopharma and its competitors with PriceTargets.com’s free daily newsletter.